PRKAA2 and neoplasm: Treating androgen-independent PC3 and PC3M cells with AICAR, an AMPK activator depending on dose or time either activated or inhibited Akt; however, in both cases mTOR activity and tumor progression was inhibited, which was found to be independent of PI3K-Akt signaling [97].